Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Lilly said patients taking Zepbound lost about 20% of their weight on average ... Both drugs are different versions of the diabetes treatments Mounjaro and Ozempic from Lilly and Novo, respectively.

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...

Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year's third quarter. The drugmaker plans to start construction of the expansion next year.

Zepbound, Mounjaro, and Ozempic can be used for weight loss. But the Food and Drug Administration (FDA) has only approved Zepbound for weight loss. Mounjaro and Ozempic are FDA approved to help ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...